Company intelligence / Profile preview
Panosome
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
Overview
Panosome has developed a proprietary platform technology, VAST, that enables the generation of high-titer antibodies against challenging targets such as small molecules, peptides, proteins, sugars, and lipids. The company is leveraging this platform to develop monoclonal antibodies for research and therapeutic use—most notably targeting tumor markers like MUC1 in pancreatic cancer. Early results indicate superior antibody titers compared to traditional methods. The company recently secured nearly €2 million in government funding to advance its lead program against pancreatic cancer into further development stages[4].
- Therapeutic areas
- ImmunologyOncology
- Modalities
- Monoclonal antibodyAntibodyNanoparticle (for delivery applications)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Panosome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Panosome.